The impact of hepatitis B virus (HBV) infection on clinical outcomes of patients with diffuse large B-cell lymphoma

European Journal of Cancer Care

Volumn 24, Issue 1, 2015, Pages 117-124

  Law, M F ^a   Lai, H K ^b   Chan, H N ^b   Ha, C Y ^b   Ng, C ^b   Yeung, Y M ^b   Yip, S F ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Clinical outcomes; Diffuse large B cell lymphoma; Hepatitis B

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTINEOPLASTIC AGENT; LAMIVUDINE; RITUXIMAB;

ADOLESCENT; ADULT; AGED; COMPARATIVE STUDY; COMPLICATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ISOLATION AND PURIFICATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; RITUXIMAB; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919839327     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12166     Document Type: Article

References (31)

1. Chan A.O., Yuen M.F., Lam C.M., Fong C.Y., Wong B.C. & Lai C.L. (2004) Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. Alimentary Pharmacology and Therapeutics 19, 401-406.
2. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P. & Gisselbrecht C. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine 346, 235-242.
3. Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., Lefort S., Marit G., Macro M., Sebban C., Belhadj K., Bordessoule D., Fermé C. & Tilly H. (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 116, 2040-2045.
4. Duberg A.S., Nordström M., Törner A., Reichard O., Strauss R., Janzon R., Bäck E. & Ekdahl K. (2005) Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology (Baltimore, Md.) 41, 652-659.
5. Engels E.A., Cho E.R. & Jee S.H. (2010) Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. The Lancet Oncology 11, 827-834.
6. European Association for the Study of the Liver (2012) EASL Clinical Practice Guidelines: management of chronic hepatitis B. Journal of Hepatology 57, 167-185.
7. Evens A.M., Jovanovic B.D., Su Y.C., Raisch D.W., Ganger D., Belknap S.M., Dai M.S., Chiu B.C., Fintel B., Cheng Y., Chuang S.S., Lee M.Y., Chen T.Y., Lin S.F. & Kuo C.Y. (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Annals of Oncology 22, 1170-1180.
8. Faggioli P., De Paschale M., Tocci A., Luoni M., Fava S., De Paoli A., Tosi A. & Cassi E. (1997) Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 82, 38-42.
9. Kim J.H., Bang Y.J., Park B.J., Yoo T., Kim C.W., Kim T.Y., Heo D.S., Lee H.S. & Kim N.K. (2002) Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Japanese Journal of Cancer Research 93, 471-477.
10. van der Kolk L.E., Baars J.W., Prins M.H. & van Oers M.H. (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100, 2257-2259.
11. Leaw S.J., Yen C.J., Huang W.T., Chen T.Y., Su W.C. & Tsao C.J. (2004) Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Annals of Hematology 83, 270-275.
12. Leung C., Tsoi E., Burns G. & Sievert W. (2011) An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. The Oncologist 16, 579-584.
13. Li Y.H., He Y.F., Jiang W.Q., Wang F.H., Lin X.B., Zhang L., Xia Z.J., Sun X.F., Huang H.Q., Lin T.Y., He Y.J. & Guan Z.Z. (2006) Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106, 1320-1325.
14. Lim S.T., Fei G., Quek R., Lim L.C., Lee L.H., Yap S.P., Loong S. & Tao M. (2007) The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis. European Journal of Haematology 79, 132-137.
15. Lok A.S. & McMahon B.J. (2007) Chronic hepatitis B. Hepatology (Baltimore, Md.) 45, 507-539.
16. Lok A.S., Liang R.H., Chiu E.K., Wong K.L., Chan T.K. & Todd D. (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 100, 182-188.
17. Lok A.S., Ward J.W., Perrillo R.P., McMahon B.J. & Liang T.J. (2012) Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable. Annals of Internal Medicine 156, 743-745.
18. Marcucci F. & Mele A. (2011) Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 117, 1792-1798.
19. Marcucci F., Mele A., Spada E., Candido A., Bianco E., Pulsoni A., Chionne P., Madonna E., Cotichini R., Barbui A., De Renzo A., Dore F., Iannitto E., Liso V., Martino B., Montanaro M., Pagano L., Musto P. & Rapicetta M. (2006) High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 91, 554-557.
20. Mele A., Pulsoni A., Bianco E., Musto P., Szklo A., Sanpaolo M.G., Iannitto E., De Renzo A., Martino B., Liso V., Andrizzi C., Pusterla S., Dore F., Maresca M., Rapicetta M., Marcucci F., Mandelli F. & Franceschi S. (2003) Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 102, 996-999.
21. Natoli G., Avantaggiati M.L., Chirillo P., Puri P.L., Ianni A., Balsano C. & Levrero M. (1994) Ras- and Rafdependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator. Oncogene 9, 2837-2843.
22. Niscola P., Del Principe M.I., Maurillo L., Venditti A., Buccisano F., Piccioni D., Amadori S. & Del Poeta G. (2005) Fulminant B hepatitis in a surface antigennegative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 19, 1840-1841.
23. Park S.C., Jeong S.H., Kim J., Han C.J., Kim Y.C., Choi K.S., Cho J.H., Lee M., Jung H.H., Ki S.S., Chang Y.H., Lee S.S., Park Y.H. & Lee K.H. (2008) High prevalence of hepatitis B or C virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea. Journal of Medical Virology 80, 960-966.
24. Pfreundschuh M., Trumper L., Osterborg A., Pettengell R., Trneny M., Imrie K., Ma D., Gill D., Walewski J., Zinzani P.L., Stahel R., Kvaloy S., Shpilberg O., Jaeger U., Hansen M., Lehtinen T., López-Guillermo A., Corrado C., Scheliga A., Milpied N., Mendila M., Rashford M., Kuhnt E., Loeffler M.; MabThera International Trial Group (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. The Lancet Oncology 7, 379-391.
25. Pfreundschuh M., Schubert J., Ziepert M., Schmits R., Mohren M., Lengfelder E., Reiser M., Nickenig C., Clemens M., Peter N., Bokemeyer C., Eimermacher H., Ho A., Hoffmann M., Mertelsmann R., Trümper L., Balleisen L., Liersch R., Metzner B., Hartmann F., Glass B., Poeschel V., Schmitz N., Ruebe C., Feller A.C., Loeffler M.; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B cell lymphomas: a randomized controlled trial (RICOVER-60). The Lancet Oncology 9, 105-116.
26. Shepard C.W., Simard E.P., Finelli L., Fiore A.E. & Bell B.P. (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiologic Reviews 28, 112-125.
27. Tsutsumi Y., Kawamura T., Saitoh S., Yamada M., Obara S., Miura T., Kanamori H., Tanaka J., Asaka M., Imamura M. & Masauzi N. (2004) Hepatitis B virus reactivation in a case of non- Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leukemia and Lymphoma 45, 627-629.
28. Wang F., Xu R.H., Han B., Shi Y.X., Luo H.Y., Jiang W.Q., Lin T.Y., Huang H.Q., Xia Z.J. & Guan Z.Z. (2007) High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 109, 1360-1364.
29. Wang X.W., Gibson M.K., Vermeulen W., Yeh H., Forrester K., Stürzbecher H.W., Hoeijmakers J.H. & Harris C.C. (1995) Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Research 55, 6012-6016.
30. Yeo W., Chan P.K., Ho W.M., Zee B., Lam K.C., Lei K.I., Chan A.T., Mok T.S., Lee J.J., Leung T.W., Zhong S. & Johnson P.J. (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. Journal of Clinical Oncology 22, 927-934.
31. Yeo W., Tung C.C., Nancy W.Y., Yeo W., Chan T.C., Leung N.W., Lam W.Y., Mo F.K., Chu M.T., Chan H.L., Hui E.P., Lei K.I., Mok T.S. & Chan P.K. (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. Journal of Clinical Oncology 27, 605-611.